|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Associations were found between toxicities and gene variants (P<0.05), including neutropenia with ABCB1 (rs1045642) and SLC0B3 (rs4149117 and rs7311358); and diarrhoea with CYP2C9 (rs1057910), CYP2C19 (rs3758581), UGT1A6 (rs4124874) and SLC22A1 (rs72552763).
|
28817838 |
2017 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In addition, a statistically significant association was found among neutropenia (absolute neutrophil count<500) and variant allele carriers of ABCB1 rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and ABCB1 rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively.
|
25007187 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
On evaluating higher order gene-gene interaction models by MDR analysis, CYP3A5*3; ABCB11236C>T and ABCB1 2677G>T/A; ABCB1 3435C>T and CYP1B1*3 showed significant association with treatment response, grade 2-4 anemia and dose delay/reduction due to neutropenia (P=0.024, P=0.004, P=0.026), respectively.
|
24704000 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
C3435T polymorphisms of ABCB1 might be able to predict severe amrubicin-induced neutropenia.
|
24982363 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
With regard to ABCB1 3435 C>T, ABCB1 3435 T/T had significantly higher risks of neutropenia (P = 0.015).
|
22271208 |
2012 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
|
21327421 |
2011 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Statistical associations were observed, suggesting a lower risk of neutropenia (p = 0.013) and hand-foot syndrome (HFS; p = 0.027) for the carriers of T variation for rs1128503 in capecitabine-treated patients, carriers of T variation for rs1045642 treated with capecitabine had a lower risk of HFS (p = 0.033), while those treated with 5-FU had a higher risk of diarrhea (p = 0.035), and carriers of T variation for rs2032592 treated with capecitabine were at less risk of developing HFS (p = 0.033).
|
21142915 |
2010 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia.
|
19349543 |
2009 |